Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126568391 | 12656839 | 1 | I | 20160810 | 20160816 | 20160816 | EXP | US-MYLANLABS-2016M1033698 | MYLAN | IRAGAVARAPU C, GUPTA T, CHUGH SS, ARONOW WS, FRISHMAN WH. TYPE B LACTIC ACIDOSIS ASSOCIATED WITH VENLAFAXINE OVERDOSE. AM-J-THER 2016;23(4):E1082-E10. | 0.00 | Y | 0.00000 | 20160816 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126568391 | 12656839 | 1 | PS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 80 CAPSULES; CUMULATIVE DOSE OF AROUND 6000MG | 77166 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126568391 | 12656839 | 1 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126568391 | 12656839 | HO |
| 126568391 | 12656839 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126568391 | 12656839 | Intentional overdose | |
| 126568391 | 12656839 | Lactic acidosis | |
| 126568391 | 12656839 | Suicide attempt |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |